Taken together, this evidence offers useful information to better clarify the role played by S100B protein in MS-related neuroinflammation, delineate the specific glial subtypes involved, and support the rationale for targeting S100B in therapeutic strategies. This evidence concerns the gene S100B and myeloid sarcoma.